AZSTARYS Now Available: Stimulant ADHD Medication Launched by Corium, Inc.

AZSTARYS, a new stimulant ADHD medication from Corium, Inc., is now available in the U.S. for patients aged 6 years and older.

By Lilly Constance Verified Updated on July 22, 2021

July 22, 2021

The new stimulant ADHD medication AZSTARYS is now available for the treatment of ADHD symptoms in patients aged 6 years and older. A once-daily methylphenidate in capsule form, AZSTARYS comprises 70% extended-release serdexmethylphenidate and dexmethylphenidate with 30% immediate-release dexmethylphenidate.

AZSTARYS was approved by the FDA earlier this year, following a double-blind, randomized, placebo-controlled, phase 3 study of 150 children aged 6 to 12 years who had been diagnosed with ADHD. The study found symptom improvement without serious adverse side effects.

Perry J. Sternberg, President and CEO of Corium, Inc., said that AZSTARYS “provides patients with ADHD, their caregivers, and their clinicians with a first-of-its-kind treatment that offers both rapid and extended ADHD symptom improvement because of the dual action of its formulation using the prodrug SDX with IR MPH.”

In a Corium press release, Greg Mattingly, M.D., of St. Charles Psychiatric Associates, added: “The availability of the first medicine to use the novel prodrug SDX expands the therapeutic options that families and their physicians can consider when deciding the most suitable ADHD symptom management treatment for children. This innovative therapy is especially significant when considering the onset and duration of its sustained therapeutic effects, which as a clinician and researcher, I know to be important properties in the development of treatments to meet the unmet medical needs of this community.”